Patients as partners
People are at the heart of Rinri’s work. Hearing loss, and how this condition affects everyday lives are central to everything we do. To ensure that we never lose sight of this, and to understand their perspectives and needs, we are working closely with people with lived experiences of hearing loss throughout the development of our cell therapy. We also work with families and carers, charities, hospitals, academic institutions and industry bodies, inside and outside the hearing loss space, to guide our development and raise awareness of hearing health.
We have worked extensively with people with hearing loss to identify the current limitations of available treatments and gather insights on the new interventions they want. Feedback from both hearing aid users and cochlear implant users highlights that existing hearing devices are perceived as “very limited” and that “normal hearing is totally different from a cochlear implant and would be wonderful…and unbelievable” In addition, we actively collaborate with people having firsthand experience of hearing loss to shape our clinical strategy and trials, ensuring alignment with their needs. Furthermore, we partner with them to create materials that effectively communicate our work in an accessible manner.
Our first product Rincell-1 is expected to enter clinical trials in 2025. It will be administered to adults with severe-to-profound age-related hearing loss or Auditory Neuropathy, eligible under UK NICE guidance (TA566) for a cochlear implant. Further details will be uploaded to our website and social media accounts as they become available. For more information, or to find out more about our patient and public involvement, please contact enquiries@rinri-therapeutics.com
Other information on hearing loss clinical trials can be found at Be Part of Research (nihr.ac.uk) and on the RNID website.
Working with clinicians
In its mission to restore hearing, Rinri Therapeutics is committed to driving responsible improvement, responding to new evidence and new ways of working in collaboration with the clinical community. As well as carrying out research with clinicians, the company receives senior leadership and strategic direction from a number of clinical key opinion leaders passionate about improving outcomes for hearing loss patients across the spectrum of hearing conditions.
In the future, when novel therapeutics are approved for the treatment of hearing loss, ENT doctors and audiologists will continue to play a pivotal role as experts in the management and treatment of people with hearing loss. Hearing professionals will shape the evolution and incorporation of Rinri’s therapeutic products into standard clinical pathways. Their contributions will continue to span from diagnosing individuals with hearing loss, guiding them through selecting an appropriate therapeutic approach, to actively designing and implementing personalised rehabilitation strategies as well as monitoring patients’ long-term hearing outcomes.
To find out more about getting involved, please contact us at clinical@rinri-therapeutics.com